scanX
Jubilant Pharmova

Jubilant Pharmova

1,174.20
-4.40
(-0.37%)
Market Cap
18,702.79 Cr
EPS
52.99
PE Ratio
33.62
Dividend Yield
0.42 %
Industry
Healthcare
52 Week High
1,309.90
52 Week Low
719.95
PB Ratio
3.00
Debt to Equity
0.68
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Jubilant Pharmova Shareholders Approve Sale of API Business to Subsidiary3 days ago
Jubilant Pharmova Limited received shareholder approval through postal ballot for the sale and transfer of its Active Pharmaceutical Ingredients (API) Business to Jubilant Biosys Limited, a wholly-owned subsidiary, on a slump sale basis. The special resolution was passed with 99.997% votes in favor, with 602 shareholders voting for the proposal and 44 against. The postal ballot process concluded on July 24, 2025, with a total of 646 shareholders participating in the e-voting process. The cut-off date for eligible shareholders was June 13, 2025, and the company had 101,083 total shareholders on record.

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,702.20
#1 4,08,414.80
35.57
#1 54,729.00
12.06
#1 10,980
-18.99
55.97
Divis Laboratories
6,584.00
1,74,784.51
80.22
9,712.00
0.89
2,191
23.05
40.37
Cipla
1,572.00
1,26,971.67
22.93
28,409.50
7.12
5,291
9.88
70.77
Torrent Pharmaceuticals
3,622.90
1,21,969.00
63.65
11,539.40
6.99
1,911
19.91
72.46
Dr Reddys Laboratories
1,287.40
1,07,442.68
#1 18.77
33,741.20
16.73
5,725
1.26
54.50
Mankind Pharma
2,541.60
1,04,899.14
61.83
12,744.20
19.57
2,007
-10.91
52.39
Zydus Life Science
980.10
98,620.99
21.15
23,511.00
13.82
4,615
-0.19
54.96
Lupin
1,960.50
89,535.15
27.44
22,909.50
#1 19.94
3,306
#1 112.49
53.75
Abbott
32,895.00
69,899.58
50.72
6,684.70
10.80
1,414
27.83
42.22
Aurobindo Pharma
1,127.00
65,456.34
18.86
31,378.10
17.55
3,366
-0.50
47.15

Automatic Screeners on ScanX

Community
10% near 52 Week High
Community
Support 1 Breached
Forecast
Actual
Growth Rate
Revenue Growth
7.15 %
Net Income Growth
-212.02 %
Cash Flow Change
47.01 %
ROE
-211.67 %
ROCE
99.13 %
EBITDA Margin (Avg.)
11.09 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
1,529
1,430
1,439
1,327
1,466
1,405
1,365
1,444
1,576
1,545
1,628
2,045
2,247
2,056
2,249
2,382
2,346
2,163
2,249
1,544
1,563
1,175
1,631
1,838
1,614
1,617
1,638
1,304
1,513
1,452
1,598
1,543
1,682
1,575
1,686
1,714
1,764
2,130
1,764
1,823
1,928
Expenses
1,323
1,121
1,129
1,061
1,192
1,051
1,045
1,126
1,293
1,219
1,336
1,651
1,794
1,663
1,828
1,899
2,262
1,747
1,798
1,141
1,131
977
1,242
1,293
1,216
1,269
1,319
1,116
1,280
1,259
1,440
1,408
1,459
1,419
1,439
1,459
1,656
1,480
1,477
1,554
1,587
EBITDA
206
309
310
266
274
354
319
318
283
327
293
394
453
393
422
483
83
415
451
403
432
199
389
546
398
348
319
187
233
192
158
134
223
156
247
255
108
650
287
269
341
Operating Profit %
13 %
21 %
21 %
20 %
19 %
25 %
23 %
22 %
17 %
21 %
18 %
19 %
19 %
19 %
19 %
19 %
4 %
19 %
20 %
24 %
24 %
13 %
20 %
26 %
22 %
21 %
19 %
14 %
15 %
13 %
9 %
8 %
12 %
9 %
14 %
12 %
5 %
14 %
15 %
14 %
17 %
Depreciation
66
70
75
75
127
72
72
73
75
73
79
82
182
88
90
98
95
103
117
84
98
82
85
96
86
88
100
93
101
95
94
94
271
90
97
95
101
91
91
91
95
Interest
85
91
92
89
99
83
80
98
80
69
66
77
73
51
54
53
62
73
72
49
47
48
47
46
43
35
35
37
40
40
42
51
56
62
66
71
73
71
61
56
53
Profit Before Tax
68
168
161
145
69
218
193
166
160
203
168
261
227
286
302
356
-40
269
292
294
358
106
299
431
297
247
208
70
106
69
36
9
-86
25
98
101
-54
500
144
131
206
Tax
25
37
36
24
58
54
50
48
11
60
43
48
74
86
92
88
61
84
43
90
98
18
75
121
83
86
65
19
47
22
32
25
14
19
36
35
8
18
42
30
55
Net Profit
43
130
125
122
11
164
144
118
149
144
126
213
152
200
210
268
-101
185
249
203
261
88
224
310
214
161
143
51
59
47
5
-16
-101
6
62
66
-62
482
103
101
151
EPS in ₹
2.68
8.28
8.11
7.90
0.72
10.39
9.29
7.66
9.63
9.44
8.23
13.64
9.94
13.00
13.50
16.74
-6.38
11.61
15.66
12.77
16.35
5.53
14.06
19.46
13.43
10.09
8.97
3.20
3.74
2.96
0.34
-0.98
-6.15
0.40
3.94
4.22
-3.69
30.44
6.47
6.37
9.71
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
6,265
Current Assets
2,715
2,875
2,948
3,190
4,585
5,038
2,953
3,509
3,762
3,876
3,510
Capital Work in Progress
597
611
684
671
901
768
897
1,090
1,562
2,103
2,715
Investments
0
85
103
124
115
69
241
239
256
42
1,129
Other Assets
3,111
3,023
3,147
3,423
4,804
5,344
3,171
3,792
4,156
4,312
68
Total Liabilities
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
Current Liabilities
2,129
2,464
1,684
2,005
2,090
2,619
1,049
1,592
1,772
1,889
2,165
Non Current Liabilities
4,036
3,432
3,968
3,578
4,570
4,299
3,128
3,083
3,993
4,238
4,353
Total Equity
2,454
2,928
3,389
4,035
4,809
5,604
4,742
5,316
5,392
5,421
6,255
Reserve & Surplus
2,438
2,951
3,421
4,071
4,793
5,588
4,726
5,303
5,383
5,418
6,239
Share Capital
16
16
16
16
16
16
16
16
16
16
16
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
Investing Activities
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
Operating Activities
783
1,099
1,269
1,303
1,122
1,543
1,784
838
661
971
Financing Activities
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-433
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
47.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
23.21 %
0.00 %
19.06 %
19.49 %
17.94 %
16.96 %
17.22 %
17.40 %
DIIs
0.78 %
1.15 %
0.40 %
0.43 %
0.05 %
0.04 %
0.39 %
1.62 %
0.40 %
1.63 %
1.65 %
1.50 %
3.78 %
4.07 %
5.66 %
6.98 %
7.05 %
9.53 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.07 %
16.98 %
19.03 %
18.97 %
19.27 %
19.35 %
19.01 %
18.68 %
18.69 %
18.25 %
18.24 %
18.76 %
18.71 %
17.79 %
18.09 %
18.09 %
17.75 %
17.97 %
Others
32.47 %
31.19 %
29.89 %
29.92 %
30.00 %
29.93 %
29.92 %
29.02 %
28.98 %
29.44 %
6.22 %
29.06 %
7.77 %
7.97 %
7.63 %
7.30 %
7.31 %
7.42 %
No of Share Holders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442
96,526
99,673

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 3 4.5 5 5 5 5 5 0.00
Dividend Yield (%) 0.00 0.36 0.45 1.81 0.73 1.29 1.79 0.88 0.56 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
29 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 Jul 2025 1,210.30 1,177.55
25 Jul 2025 DIVIDEND Dividend
₹ 5.00 /share
 25 Jul 2025 905.60 1,175.00
16 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 16 May 2025 896.35 905.60
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jan 2025 937.70 954.95
25 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 25 Oct 2024 1,228.25 1,108.05
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 30 Aug 2024 849.00 920.60
02 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
 02 Aug 2024 703.90 866.20
10 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
 10 Aug 2023 362.90 404.75
12 Aug 2022 DIVIDEND Dividend
₹ 5.00 /share
 11 Aug 2022 397.10 353.35
06 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
 05 Aug 2021 843.05 657.45
01 Feb 2021 CHANGE OF NAME Change Of Name
NA
 01 Feb 2021 886.60 886.60

Announcements

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report3 days ago
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 20255 days ago
Disclosure Under Regulation 305 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 25, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 16, 2025
Board Meeting Outcome for Outcome Of Board MeetingJun 12, 2025
Announcement under Regulation 30 (LODR)-RestructuringJun 12, 2025
Intimation Under Regulation 30 - Receipt Of Rectification Order From The Income Tax DepartmentJun 11, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 04, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 16, 2025
The Company Has Informed The Exchange That Record Date For The Purpose Of Dividend Is July 25 2025.May 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 16, 2025
Corporate Action-Board approves DividendMay 16, 2025
Audited Results For The Quarter And Financial Year Ended March 31 2025May 16, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 16 2025May 16, 2025
Announcement under Regulation 30 (LODR)-Credit RatingMay 06, 2025
Board Meeting Intimation for 1. The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31 2025. 2. Recommendation Of Final Dividend If Any For The Financial Year Ended March 31 2025.Apr 30, 2025
Update On Material Development About The Disclosure Made On February 25 2025Apr 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Amended And Restated Deed Of Private Trust Dated March 25 2025Mar 25, 2025
Closure of Trading WindowMar 24, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Jubilant Biosys Innovative Research Services Pte Limited Singapore Has Executed Shareholders Agreement And Other Transition Agreements With PieMar 20, 2025
Announcement Under Regulation 30 - USFDA Report For Jubilant Cadista Pharmaceuticals Inc. USAMar 12, 2025
Rumour verification - Regulation 30(11)Feb 25, 2025
Audio Recording Of Investors / Analysts MeetingFeb 24, 2025
Presentation For Investor And Analyst MeetFeb 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 01, 2025
Integrated Filing (Financial)Jan 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 31, 2025
Unaudited Results For The Quarter Ended December 31 2024Jan 31, 2025
Board Meeting Outcome for Outcome Of Board MeetingJan 31, 2025
Announcement Under Regulation 30 - Jubilant Biosys Innovative Research Services Pte Limited Singapore (JBIRSPL) A Subsidiary Of Jubilant Biosys Limited A Wholly Owned Subsidiary Of The Company Has ExeJan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 27, 2025
The Company Has Informed The Prepayment Of USD 25 Million Term Loan Equivalent To Rs. 214 Cr.Jan 24, 2025
Board Meeting Intimation for Intimation For Board Meeting Scheduled On January 31 2025 To Consider The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Jan 23, 2025
USFDA Inspection In Companys Subsidiary Jubilant Cadista Pharmaceuticals Inc.Jan 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 15, 2025
Announcement under Regulation 30 (LODR)-Credit RatingDec 10, 2024
Deferment Of Investor/ Analysts MeetingNov 05, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 27, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 25, 2024
Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024Oct 25, 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held On October 25, 2024 - Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024Oct 25, 2024

Technical Indicators

RSI(14)
Neutral
51.43
ATR(14)
Less Volatile
36.68
STOCH(9,6)
Neutral
45.29
STOCH RSI(14)
Oversold
3.58
MACD(12,26)
Bearish
-6.27
ADX(14)
Weak Trend
23.04
UO(9)
Bearish
49.88
ROC(12)
Uptrend And Accelerating
2.59
WillR(14)
Neutral
-64.76
Bearish
4
Neutral
3
Bullish
2

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Kotak Multicap Fund Direct - Growth
1.15%
1800000
1.15%
1.15%
HDFC Manufacturing Fund Direct - Growth
0.50%
500000
0.50%
0.50%
Bandhan Small Cap Fund Direct-Growth
1.23%
439100
0.35%
0.55%
Kotak Special Opportunities Fund Direct-Growth
3.72%
200000
1.19%
1.70%
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
-63185
-0.85%
-0.69%
Motilal Oswal Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
-47763
-0.85%
-0.69%
Bandhan Innovation Fund Direct-Growth
1.59%
30900
0.18%
0.49%
Axis Nifty500 Momentum 50 Index Fund Direct-Growth
0.00%
-4892
-0.84%
-0.68%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.45%
2343
-0.02%
0.06%
Bandhan Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
-1721
-0.85%
-0.69%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.45%
1014
-0.02%
0.06%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.45%
476
-0.02%
0.06%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.45%
398
-0.01%
0.06%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.20%
-314
-0.03%
0.01%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.11%
-146
-0.01%
0.01%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.45%
143
-0.02%
0.06%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.45%
80
-0.02%
0.06%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.45%
74
-0.02%
0.06%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.05%
71
0.00%
0.01%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.45%
26
-0.01%
0.06%
HDFC BSE 500 Index Fund Direct - Growth
0.05%
23
0.00%
0.01%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.45%
20
-0.01%
0.06%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.70%
18
0.00%
0.16%
Groww Nifty Total Market Index Fund Direct - Growth
0.04%
16
0.00%
0.01%
SBI Nifty 500 Index Fund Direct-Growth
0.05%
-14
0.00%
0.01%

About Jubilant Pharmova

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Website
https://www.jubl.com
Chairperson NameShyam S Bhartia
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Intraday Screeners
Technical Screeners
Candlestick Screeners
Price & Volume Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104